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Increasing clarity in the deﬁ  nition of cellular physiobiochemical mechanisms and the 
inter-relationships with regulatory molecules has put forth an increasingly reﬁ  ned 
framework for viewing and understanding potential therapeutic targets. The ability to 
synthesize and deliver as drugs, endogenous or exogenous proteins or nucleic acids in 
their native or altered state has also evolved along with this knowledge. Tools devel-
oped for modeling of proteins have also greatly accelerated the development of small 
molecule ligands developed as nominally speciﬁ  c drugs. Technology advancements 
have expanded our therapeutic armamentarium from sera to recombinant proteins, to 
intact cells. These novel therapeutic arts clearly did not exist in the days of old, thus 
deserves a name, perhaps biologics.
However, the term ‘biologics’ has already been taken many years earlier, and 
has been a staple of the pharmacological, medical and legal lexicon since. The legal 
deﬁ  nition of biologics originally included biological therapeutic substances with more 
obvious rationale (blood products, tissues, cells, vaccines) as well as novel targeted 
agents, but excludes small-molecule targeted agents which should be included under 
‘biologics’. Explosive growth of therapies derived on the basis of macromolecular 
and molecular understanding of the speciﬁ  c disease pathology will likely render this 
a moot point, because such therapies will surely dominate in number as compared 
with other therapies included under this rubric. 
The more narrow interpretation of biologics would not include small molecule 
drugs, but because of the widespread use of in-silico drug-design, an increasing number 
of drugs are actually products of the art of biologics; certainly ACE-inhibitors, calcium 
channel inhibitors, H2-antagonists, proton-pump inhibitors, statins, β-lactam inhibi-
tors, thrombin-inhibitors, and cyclo-oxygenase inhibitors represent the vast majority 
of all prescribed drugs. Present day versions of these classes of drugs are clearly and 
rationally designed utilizing the art of biologics. Since the number of drugs without 
clearly deﬁ  ned rationale in the framework of physiobiochemical pathways and regula-
tory molecules appears to be shrinking, it appears that the art of biologics has already 
permeated pharmacotherapy.
We ascribe the broader deﬁ  nition of biologics as the art of preparing, testing, and 
therapeutically perfecting the methods of clinical use of molecules of any size or origin, 
or cells to speciﬁ  cally target (activate, inactivate, or regulate) critical physiobiochemi-
cal mechanisms in order to gain therapeutic advantage. Because these mechanisms 
are interwoven for many clinically distinct diseases, dissemination of information 
across disciplines of medicine is imperative for development of optimal application 
in improving comfort and perhaps, an interdisciplinary sparks of imagination that will 
lead to new healing applications for myriad diseases.
The inaugural issue of Biologics: Targets and Therapy provides a glimpse into the 
state of the art and present clinical applicability of biologics in the ﬁ  elds of perinatology, 
transplant immunology, rheumatology, dermatology, and oncology. The diverse targets 
range from anatomical lesions in the brain to cell-surface epitopes, to intracellular kinases 
reﬂ  ect an increasingly wide range of rationally designed pharmacological agents that as 
a whole have had a tremendous impact on suffering from disease conditions previously 
refractory to therapy, as well as on the natural history of disease, and the socioeconomic 
health of healthcare systems. Common themes encountered in papers describing thera-
peutic endeavors with biologics are uncertainties regarding deﬁ  nitions of the disease and 
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response criteria, dose and timing or therapy, adverse effects 
due to immune/inﬂ  ammatory system interactions or imprecise 
targeting, potential for devastating unanticipated adverse 
events, and for some agents, striking efﬁ  cacy unparalleled by 
any other previously existing therapy.
RSV pneumonia is recognized as risk factor for perinatal 
hospitalization for pulmonary ailments, particularly in the pre-
mature or otherwise ill infants. Palivizumab, an anti-RSV-G 
protein antibody confers a reduction in the frequency of repeat 
hospitalization in high-risk infants, whereas when given in the 
setting of active RSV-pneumonia, no beneﬁ  t is seen. There 
is much debate regarding Palivizumab prophylaxis because 
of varying deﬁ  nitions of high-risk, yearly variation in sever-
ity of RSV infections, and perhaps geographically isolated 
genetic susceptibility factors. Certainly, administration after 
established RSV is not acutely beneﬁ  cial, but passive im-
munity conferred by its administration appears beneﬁ  cial 
in the majority of studies. These as well as studies of the 
TNFα-blocking drugs and kinase inhibitors emphasize the 
importance of carefully deﬁ  ning the disease populations under 
study and the outcome variables.
Because the targeting of TNFα at the cell surface is 
particularly convenient, and because this molecule controls 
a very large number of stress-response events, it is not at all 
surprising that agents targeting TNFα signaling are being 
applied clinically, and quite successfully, to a number of 
conditions including psoriasis, psoriatic-arthritis, ankylos-
ing spondylitis, and inﬂ  ammatory bowel disease. The large 
number of signaling pathways affected directly or indirectly 
by TNFα is also certainly responsible for the wide array of 
adverse effects. With improvement in deﬁ  nitions of pathways 
down-stream of TNFα, it is possible that additional or alter-
native interventions speciﬁ  cally attacking the target involved 
in pathogenesis, while sparing bystanders can develop. Care-
ful documentation of adverse effects and circumstances, thus, 
can be very valuable future retrospective analyses seeking 
evidence for proposed pathways.
Whereas signaling pathways are generally well described 
in these papers, consistently absent are meaningful discus-
sions of the effect of these signaling molecule in terms of 
biochemical effects. A much better understanding of the 
reasons for adverse effects, and rationale for reconsideration 
of targets and agents, and methods of optimization of biolog-
ics using concomitant small molecule therapy could develop 
when signaling is juxtaposed with biochemistry. An recent 
example relates to the role of lipid-hydroperoxide metabolism 
of the enzyme aldose reductase. Depletion or inhibition of 
aldose-reductase has now been shown in models of sepsis, 
shock, and malignancy to abrogate signiﬁ  cant aspects of 
TNF-α-mediated signaling. These ﬁ  ndings suggest that 
targeting down-stream of TNFα could give rise to a more 
speciﬁ  c or less toxic therapy.
As is unavoidable, once drugs originated through biologics 
become part of clinical practice within medical subspecialty, 
there is a tendency to expand application to related disorders 
not necessarily covered by initial indications. Such attempts 
are viewed with a jaundiced eye by third party payors, but in 
clinical trial settings, very meaningful results can be found. 
Whereas dramatic and unquestionable effectiveness of 
many biologic therapies have been seen in all ﬁ  elds of medi-
cine, it remains a therapeutic art in its infancy, not yet fully 
deﬁ  ned as to the scope of potential therapies to be included 
within it. Even the best established biologics, vaccines, have 
incompletely deﬁ  ned mechanisms, and application of novel 
paradigms exploiting recent ﬁ  ndings regarding mechanisms 
of immunity and autoimmunity are on the horizon. In the 
present issue, Dr. Barabas’ review puts forth a novel view 
of mechanisms leading to autoimmune phenomenon, and 
how a vaccine approach utilizing IgM-antigen complexes 
may be useful for treatment of autoimmune renal disease. 
The seemingly simple concept appears to have merit at least 
in animal models, and suggests a novel biologic approach to 
treatment of other autoimmune disorders. Stem cell therapies 
also hold enormous promise, and are certainly in the spotlight 
in the political arena. Though the present state of the art is 
still signiﬁ  cantly distanced from clinical applicability, some 
promising developments combined with optimism regarding 
the development of targeted drugs to enhance engraftment 
and differentiation of stem cells are hopeful signs.
This inaugural issue puts forth the current state of the 
art and of opinion leaders from a small sampling of some of 
rationally derived therapeutic agents we refer to collectively 
as biologics, not necessarily because of their chemical com-
position, but because of their conception and development 
within the new art of biologics.
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